



Pharsight Signs Tobira Therapeutics as PKS Online™ Customer

Specialty Biopharmaceutical Company Adopts Pharsight On-Demand Software to Enable Centralized, Integrated Management and Analysis of Clinical Research Data

ST. LOUIS, MO – March 29, 2011 – Pharsight, a market-leading provider of software and scientific consulting services to improve productivity and decision-making in clinical drug development, announced today that Tobira Therapeutics Inc., a biopharmaceutical company focused on developing and commercializing innovative products for the treatment of HIV disease, has selected PKS Online™ to support study analysis, data management, and reporting for its promising lead drug candidate, Cenicriviroc.

PKS Online is a Software-as-a-Service (“SaaS”) implementation of Pharsight Knowledgebase Server™ (PKS™), the company’s enterprise data management system for secure storage and tracking of pharmacokinetic and pharmacodynamic (PK/PD) data and analyses, that lets customers realize the benefits of a regulatory-compliant PK repository without upfront capital expenditure. Data, analyses and related files are maintained by PKS Online, which is accessed over the Internet from secure, networked desktop computers using a standard web browser or Pharsight’s analysis tools.

PKS Online serves as a central hub for sponsors and their development partners to ensure that study data, analysis and predictive models are maintained securely and efficiently. With PKS Online, studies can be exported in CDISC format for regulatory submission. PKS Online can also simplify the many data management tasks required to create multi-study analyses and prepare pharmacometric models, which FDA increasingly expects sponsors to have in place early in development.

“PKS Online provides measurable efficiencies to Tobira, eliminating the need for deployment, validation and management of an in-house system,” said David Martin, PharmD, MBA, Senior Vice President of Drug Development and Regulatory Affairs at Tobira. “With PKS Online, I have real-time visibility and streamlined access to time-critical analyses and study results, available on my desktop, to readily share with our management team, scientific advisors, and other key stakeholders.”

“We are pleased to deliver the benefits of PKS, via software-as-a-service, to a dynamic company such as Tobira,” said JF Marier, Ph.D., FCP Vice President and Lead Scientist at Pharsight. “PKS Online provides a foundation for more rational and cost effective drug development by improving scientific productivity and compliance and dramatically reducing IT overhead. This is especially important for small and specialty biopharmaceutical sponsors that need to add clear value to their portfolios. We look forward to continuing our collaboration with Tobira as their preferred PK services provider, and to helping them fully leverage the benefits of PKS Online to meet their drug development objectives.”

About PKS Online

PKS Online is an Internet-accessible implementation of Pharsight Knowledgebase Server™ (PKS), the company’s clinical trial data repository for secure storage and tracking of PK/PD data and analyses. Using a standard desktop computer and a standard network connection, PK scientists, data managers, review staff and a sponsor’s external development partners can access PKS Online through a secure channel from virtually anywhere and at anytime. PKS Online is fully integrated with Phoenix® WinNonlin®, Phoenix® Connect™ and earlier versions of WinNonlin®, as well as Pharsight’s software tools for PK analysis automation and reporting. PKS Online is offered on a subscription basis, with flexible licensing and validation support services. More information about PKS Online is available at www.pharsight.com/pksonline.php.

About Pharsight

Pharsight, a Certara™ company, is a market-leading provider of software products and scientific consulting services to help pharmaceutical and biotechnology companies improve their drug development process, regulatory compliance and strategic decision-making. Established in 1995, the company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products. Headquartered in St. Louis, Missouri, with more than 1200 customers worldwide, Pharsight products and services are used by all of the world’s top 50 pharmaceutical firms. More information about Pharsight is available at www.pharsight.com.

About Tobira Therapeutics

Tobira Therapeutics Inc. is a private biopharmaceutical company focused on developing and commercializing innovative antiviral compounds to treat HIV disease. Founded in 2006, Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development. The company’s lead compound, Cenicriviroc (TBR-652), is a potent antagonist of both CCR5, a co-

receptor required for HIV infection, and CCR2, a co-receptor that is prominently involved in a number of metabolic and cardiovascular diseases. Additional information about Tobira is available at www.tobiratherapeutics.com.

Registered Trademarks and Trademarks

Pharsight, Pharsight Knowledgebase Server, PKS, PKS Online, Phoenix, Phoenix WinNonlin, Phoenix Connect and WinNonlin are trademarks or registered trademarks of Tripos, L.P. All other brands and product names are trademarks or registered trademarks of their respective holders.

Pharsight Contact:

Adam Rutkin, 408-737-6053

Director of Marketing

arutkin@pharsight.com

##